Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of
about
Adiponectin lowers glucose production by increasing SOGAExercise training, genetics and type 2 diabetes-related phenotypes.Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Sequence variation in PPARG may underlie differential response to troglitazone.Clinical translation of genetic predictors for type 2 diabetes.Pharmacogenetics of Anti-Diabetes Drugs.Inherited destiny? Genetics and gestational diabetes mellitus.Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Pharmacogenetics in type 2 diabetes: potential implications for clinical practiceThe PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics.Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteersEffects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease.Pharmacogenetics of thiazolidinedione therapy.Pharmacogenetics of glucose-lowering drug treatment: a systematic review.Pharmacogenetics of the PPAR genes and cardiovascular disease.Pharmacogenetics: potential role in the treatment of diabetes and obesityGenetic architecture of type 2 diabetes: recent progress and clinical implicationsGenetic susceptibility to type 2 diabetes and implications for therapy.The genetics of type 2 diabetes: what have we learned from GWAS?Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.The genetics of type 2 diabetes and its clinical relevance.[Screening and prevention of diabetes].Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients.
P2860
Q24298469-F42AC5C2-99DD-496B-A15B-2C860611F05FQ30417635-5357089F-A085-4C73-89D3-C771DD2A2A03Q30571118-027AA2DB-3C32-450C-9B9E-8692DADADB6DQ34072562-68EE19B2-04F1-417D-9E4E-29010E2DCE0FQ34124681-9ADE7603-19AD-4C65-8332-7746A0E08C19Q34181995-2B8469EF-BBCA-4A11-BAD2-18E66CD5E19EQ34971477-4774DA56-1F72-49CD-8C1D-6DDF6032FE08Q35039274-F98E5FD6-9312-4480-A634-C65DFA9AFE21Q35840645-43ABDC17-E1A0-4BAA-89F3-91B26CD97554Q36326205-1C7A7CA7-ECAF-4C67-B462-7DFCCC601E12Q36441465-41BF3306-A3EF-444F-897B-AA2A0585E69EQ36475040-5E2327A1-DD0C-4264-A4EE-6585B441E39FQ36496755-E81A3778-62C7-4992-BDB6-250F791924A2Q36528512-8F9CC9E3-91B9-4307-924D-6C8E92A7F36FQ36918107-F8DAFB5F-6665-4FFB-9E9C-EE5C93418304Q36982648-FD03930B-B817-4852-B7C0-4B13783A217EQ37012017-7B9C0C39-59AC-44BF-B2E8-ED40B6D19965Q37142047-75EE517F-8A35-4DFE-A96D-FF4F1C61DFC9Q37189221-ABD4959C-6A41-4B60-9A56-3B619DDF54A8Q37689851-D72448F3-2D98-4197-9A5F-093D4CF7CDB8Q37811045-EAD5451F-18B5-42E2-9F4B-04401DC5B6D6Q37822185-34560409-8C80-448D-9361-B92AF8A5B7FEQ38061186-68B6BC97-E4AC-4768-83C5-AC901B80E343Q41274592-1854F6B6-91DE-4484-8B51-98F2E99FC8C7Q46794502-8D58A593-4864-4875-BA80-32B625A8DABF
P2860
Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@ast
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@en
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@nl
type
label
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@ast
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@en
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@nl
prefLabel
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@ast
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@en
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@nl
P2093
P2860
P1433
P1476
Changes in insulin sensitivity ...... Troglitazone in Prevention of
@en
P2093
Anny H Xiang
Aura Marroquin
Cesar Ochoa
Ifeanyi Ani
Jose Goico
Richard M Watanabe
Soren Snitker
Thomas A Buchanan
Troglitazone in Prevention of Diabetes (TRIPOD) study
P2860
P304
P356
10.2337/DIACARE.27.6.1365
P407
P577
2004-06-01T00:00:00Z